Investigator Awards In Health Policy Research 53 Bay State Road
Boston University Health Policy Institute
Boston, MA 02215 		Tel: 1-617-353-9220, ext. 1
Fax: 1-617-353-9227
Email: rwjfihp@bu.edu
www.investigatorawards.org
www.rwjf.org
Investigators And Their Projects » Areas of Expertise:
Section Info
This section contains information about all of the projects and researchers that have been funded through the Investigator Awards program since the first grants were made in 1993. The indexes in this section can be used to identify investigators by name, area of expertise, or year of award. Throughout the site, you will find that each investigator’s name links to details including contact and project information.
»List Investigators & Projects by
Experts on Aging:
Investigator names link to complete details.
Jason Karlawish, M.D.

Expertise:
Aging; Bioethics; Politics of Aging

The Making and Unmaking of Alzheimers Disease
Award Year: 2008

»Show Abstract
When is Alzheimer's disease (AD) a diagnosis and when is it a prediction? As we develop new tests to identify a person's propensity for the disease, and as we expand the definition of Alzheimer's to include patients with "preclinical AD", "prodromal AD", and mild cognitive impairment, we blur the line between diagnosis and risk assessment. With that comes the potential to harm patients and to overburden our system by treating what is actually normal, age-related cognitive change. Jason Karlawish, M.D. explores how our understanding of brain aging is changing and raising controversies. In his project, The Making and Unmaking of Alzheimer's Disease, he examines issues such as disagreements among experts about how to define and treat dementia, the use of neuroimaging, Medicare reimbursement for PET scans, genetic testing, healthy brain initiatives, and the emerging market for brain fitness activities. Dr. Karlawish considers the actors involved - from clinicians, researchers, and pharma to advocacy organizations, patients, and families - as well as the ethical, economic, and policy implications of changes in how AD is defined and measured. The project's results will contribute to policy debates about the value of costly testing, preventive treatments, and public health initiatives to maintain brain health.